Federal scientists reviewing the animal evidence on glyphosate, the active ingredient in Roundup and other weed killers, say there is high-confidence evidence that exposure reduces overall sperm health and sperm abundance in the mammals studied — findings that arrive while the Environmental Protection Agency is in the middle of deciding whether the herbicide keeps its federal registration.
The systematic review and meta-analysis, led by Brandiese E. Beverly of the National Institute of Environmental Health Sciences and published this month in Environment International, examined 55 studies of glyphosate and glyphosate-based herbicides in non-human mammals. The researchers, working under a prespecified protocol in the federal OHAT systematic review framework, searched five scientific databases through April 2026.
Most of the 55 studies reported decreased sperm motility and abundance, increased abnormal sperm morphology, and decreased testosterone following exposure to glyphosate or to glyphosate-based herbicides, the paper says. Its meta-analyses found inverse associations between exposure and sperm motility, count, concentration and testosterone. The authors rated their confidence as high that glyphosate and the formulated herbicides decrease overall sperm health and sperm abundance, and that the formulations reduce sperm motility and increase abnormal sperm morphology; they rated as moderate their confidence that glyphosate reduces sperm motility and increases abnormal sperm morphology, and that both reduce testosterone. Testosterone reductions were most consistent in juvenile or adult animals and, for the formulated herbicides, after exposures of 30 days or longer.

The evidence is from animal studies. The review did not study people, and the authors note that human exposure is primarily to glyphosate-based herbicides, with the highest exposures in occupational settings and widespread lower-level exposure through diet and drinking water.
The review exists because the U.S. Department of Health and Human Services asked for it. In late 2025, HHS asked the Division of Translational Toxicology at NIEHS to evaluate whether exposure to glyphosate or glyphosate-based herbicides is associated with carcinogenicity or male reproductive health outcomes, according to NIEHS. The animal review is the first phase of the male reproductive health project; a review of the human and mechanistic evidence is planned as the second phase.
The findings feed into a decision that belongs to EPA. The agency is reevaluating glyphosate through its pesticide registration review under the Federal Insecticide, Fungicide, and Rodenticide Act. On August 25, 2026, EPA released the results of its open literature search for the forthcoming human health risk assessment and asked the public to identify studies it may have missed; after a 60-day extension published in the Federal Register, that comment period closes on November 23, 2026.
On September 23, 2026, EPA and HHS announced a memorandum of understanding to strengthen scientific coordination and expand the evidence available to the registration review. The agreement sets up a joint technical working group drawn from EPA’s Office of Pesticide Programs and HHS components including NIEHS, the National Toxicology Program, the National Cancer Institute, the National Institute for Occupational Safety and Health, the Centers for Disease Control and Prevention’s National Center for Environmental Health, and the Food and Drug Administration, with focus areas including the toxicology of glyphosate formulations and surfactants, occupational epidemiology, human exposure and biomonitoring, and dietary exposure.
“FIFRA requires us to reexamine registered pesticides on a recurring cycle against the best available science, and that is exactly what we are doing with glyphosate,” EPA Administrator Lee Zeldin said in the announcement. EPA retains sole authority for registration decisions under FIFRA, and the agencies said the agreement creates no new authority for either agency and does not predetermine the outcome of the review. EPA is updating its human health risk assessment and its evaluation of glyphosate’s carcinogenic potential, with completion anticipated in early 2027.

